---
document_datetime: 2025-12-29 07:42:34
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/tecnemab-k1.html
document_name: tecnemab-k1.html
version: success
processing_time: 0.030126
conversion_datetime: 2025-12-30 08:36:11.498579
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Tecnemab K1

[RSS](/en/individual-human-medicine.xml/66894)

##### Withdrawn

This medicine's authorisation has been withdrawn

anti-melanoma mab fragments Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

The marketing authorisation for Tecnemab K1 has been withdrawn at the request of the marketing authorisation holder.

## Product information

31/12/2009

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

## Product details

Name of medicine Tecnemab K1 Active substance anti-melanoma mab fragments International non-proprietary name (INN) or common name anti-melanoma mab fragments Therapeutic area (MeSH) Radioimmunodetection Anatomical therapeutic chemical (ATC) code V09IA02

### Pharmacotherapeutic group

Diagnostic radiopharmaceuticals

### Therapeutic indication

As an adjunct to other diagnostic procedures for visualization by radioimmunoscintigraphy (RIS) of regional lymph node and distant metastases in the staging and follow-up of patients with stage I-III melanoma. Aid in differential diagnosis of suspected ocular melanoma.

## Authorisation details

EMA product number EMEA/H/C/000068 Marketing authorisation holder

Amersham Sorin.S.r.l.

,

Marketing authorisation issued 05/09/1996

**This page was last updated on** 31/12/2009

## Share this page

[Back to top](#main-content)